Observational Study of Tolebrutinib in MS Patients
An observational study was planned to enroll 3000 multiple sclerosis (MS) patients aged over 18 starting treatment with tolebrutinib. The study aimed to assess various socio-demographic and disease history characteristics, although no results or findings are currently available.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
This study is significant as it collects critical data on the characteristics and treatment histories of MS patients before starting a new therapy, which can help inform future treatment protocols.
What this does not prove
No results have been posted yet, making it impossible to draw any conclusions from the planned endpoints or enrollment. This absence limits the ability to evaluate the impact of tolebrutinib in the study population.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 3000 · planned enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- MS patients aged more than 18 years who are planned to start treatment with tolebrutinib treatment according to the approved local label.
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (13)
study phaseStudy type: Observational
study designStudy type: Observational
subjectsParticipants: people; ages from 18 Years; sex All
sample sizeEnrollment: 3000 participants (estimated)
relevant ms typesConditions: Multiple Sclerosis
interventionInterventions: Tolebrutinib
population"studyPopulation": "MS patients aged more than 18 years who are planned to start treatment with tolebrutinib treatment according to the approved local label.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
primary endpointPrimary endpoints: Socio-demographic Characteristics; Disease History: Most Recent Disability Status Scale (EDSS) score; Disease History: EDSS Progression in Past 12 Months; Disease History: Time Since Relapsing-Remitting Multiple Sclerosis (RRMS) Symptom Onset; Disease History: Time Since Secondary Progressive Multiple Sclerosis (SPMS) Diagnosis; Disease History: Time Since Most Recent Clinical Relapse; Disease History: Number and Type of Previous MS Treatments; Disease History: Number and Type of Prior and Current Disease Modifying Therapies (DMTs); Disease History: Number of Participants with Comorbidities; Disease History: Number of Participants with Medical History; Disease History: Number of Participants with Concomitant Medication; Magnetic Resonance Imaging Data
follow upFollow-up: Baseline; Baseline up to 36 months
sample size basisEnrollment: 3000 participants (estimated)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.